Nanobiotix (NBTX) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer.
The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical control at The University of Texas MD Anderson Cancer Center.
The treatment was well-tolerated, and investigators concluded that its favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial, the company said.
Following positive results, MD Anderson received US FDA clearance for an additional cohort studying NBTXR3 with chemoradiation. Recruitment for the new cohort is ongoing.
Nanobiotix anticipates that MD Anderson will present full results from the completed study phases at a medical congress in H1 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。